Doxorubicin‐Induced Cardiomyopathy in Children

Mancilla, Trevi R.; Iskra, Brian; Aune, Gregory J.

doi:10.1002/cphy.c180017

Cited by 108Chemotherapy-induced cardiotoxicity and mitigationCardiomyopathy and Myosin StudiesCardiovascular Function and Risk Factors

Doxorubicin‐Induced Cardiomyopathy in Children

Open access

Mancilla, Trevi R., Iskra, Brian, Aune, Gregory J.·2019·Comprehensive Physiology

DOI 10.1002/cphy.c180017PMC PMC7000168

Open this paper in CoChat — free account

Abstract

Doxorubicin‐induced cardiotoxicity in childhood cancer survivors is a growing problem. The population of patients at risk for cardiovascular disease is steadily increasing, as five‐year survival rates for all types of childhood cancers continue to improve. Doxorubicin affects the developing heart differently from the adult heart and in a subset of exposed patients, childhood exposure leads to late, irreversible cardiomyopathy. Notably, the prevalence of late‐onset toxicity is increasing in parallel with improved survival. By the year 2020, it is estimated that there will be 500,000 childhood cancer survivors and over 50,000 of them will suffer from doxorubicin‐induced cardiotoxicity. The majority of the research to‐date, concentrated on childhood cancer survivors, has focused mostly on clinical outcomes through well‐designed epidemiological and retrospective cohort studies. Preclinical studies have elucidated many of the cellular mechanisms that elicit acute toxicity in cardiomyocytes. However, more research is needed in the areas of early‐ and late‐onset cardiotoxicity and more importantly improving the scientific understanding of how other cells present in the cardiac milieu are impacted by doxorubicin exposure. The overall goal of this review is to succinctly summarize the major clinical and preclinical studies focused on doxorubicin‐induced cardiotoxicity. As the prevalence of patients affected by doxorubicin exposure continues to increase, it is imperative that the major gaps in existing research are identified and subsequently utilized to develop appropriate research priorities for the coming years. Well‐designed preclinical research models will enhance our understanding of the pathophysiology of doxorubicin‐induced cardiotoxicity and directly lead to better diagnosis, treatment, and prevention. © 2019 American Physiological Society.Compr Physiol 9:905‐931, 2019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cphy.c180017

Cites

362 of 362 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The cumulative anthracycline dose is a major risk factor for severe cardiomyopathy development, but young age at treatment, female sex, peak drug exposure and additional stress to the heart have also been implicated.
“The cumulative anthracycline dose is a major risk factor for severe cardiomyopathy development but young age at treatment, female sex, peak drug exposure and additional stress to the heart have also been implicated 161,162,163 .”
From Osteosarcoma (2022) · cites this paper as [161]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy
Suliman, H. B., Carraway, M. S., Ali, A. S., Reynolds, C. M., Welty‐Wolf, K. E., & Piantadosi, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32967 · Cited by 255 · see citing works
Retracted
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536 · see citing works
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782 · see citing works
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029 · see citing works
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,784 · see citing works
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T. I., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N. M., Hobbie, W. L., Kadan‐Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597 · see citing works
Evidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130 · see citing works
Physical Activity, All-Cause Mortality, and Longevity of College Alumni
Paffenbarger, R. S., Hyde, R., Wing, A. L., & Hsieh, C.-C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141003 · Cited by 2,742 · see citing works
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · see citing works
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
Hoff, D. D. V., LAYARD, M. W., BASA, P., DAVIS, H. L., HOFF, A. L. V., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,388 · see citing works
Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging
Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., Hofer, T., Seo, A. Y., Sullivan, R., Jobling, W. A., et al. (2005) · Science · doi:10.1126/science.1112125 · Cited by 2,165 · see citing works
Long-term trends in the incidence of and survival with heart failure
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K. L., Murabito, J. M., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020265 · Cited by 2,152 · see citing works
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,129 · see citing works
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030 · see citing works
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa‐Khalfe, T., Lu, L., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,959 · see citing works
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739 · see citing works
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,542 · see citing works
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S. P., Crijns, H. J. G. M., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,425 · see citing works
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Pérez‐Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,397 · see citing works
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
Allen, T. M., Hansen, C., Martin, F., Redemann, C. T., & Yau‐Young, A. O. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90246-5 · Cited by 1,392 · see citing works
A meta-analysis of physical activity in the prevention of coronary heart disease.
BERLIN, J. A., & COLDITZ, G. A. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115704 · Cited by 1,382 · see citing works
Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study
Wagner, A., Mahrholdt, H., Holly, T. A., Elliott, M. D., Regenfus, M., Parker, M. A., Klocke, F. J., Bonow, R. O., Kim, R. J., & Judd, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12389-6 · Cited by 1,306 · see citing works
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
Mulrooney, D. A., Yeazel, M. W., Kawashima, T. I., Mertens, A. C., Mitby, P. A., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,171 · see citing works
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K. R., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111 · see citing works
Doxorubicin Cardiomyopathy
Chatterjee, K., Zhang, J., Honbo, N. Y., & Karliner, J. S. (2009) · Cardiology · doi:10.1159/000265166 · Cited by 1,074 · see citing works
Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children
Towbin, J. A., Lowe, A. M., Colan, S. D., Sleeper, L. A., Orav, E. J., Clunie, S. K., Messere, J. E., Cox, G. F., Lurie, P. R., Hsu, D. T., et al. (2006) · JAMA · doi:10.1001/jama.296.15.1867 · Cited by 1,055 · see citing works
More ‘Malignant’ Than Cancer? Five-Year Survival Following a First Admission for Heart Failure
Stewart, S., Macintyre, K., Hole, D. J., Capewell, S., & McMurray, J. J. V. (2001) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00141-0 · Cited by 1,049 · see citing works
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable?
Bellenger, N. G. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2011 · Cited by 1,028 · see citing works
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Maceira, A. M., Joshi, J., Prasad, S. K., Moon, J., Perugini, E., Harding, I., Sheppard, M. N., Poole-Wilson, P. A., Hawkins, P. N., & Pennell, D. J. (2005) · Circulation · doi:10.1161/01.cir.0000152819.97857.9d · Cited by 982 · see citing works
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
Cardinale, D. M., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F. A., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 951 · see citing works
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903 · see citing works
Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the Human
Burnett, J. C., Kao, P.-C., Hu, D. C., Heser, D. W., Heublein, D. M., Granger, J. P., Opgenorth, T. J., & Reeder, G. S. (1986) · Science · doi:10.1126/science.2935937 · Cited by 890 · see citing works
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 874 · see citing works
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 828 · see citing works
The biosynthesis and functional role of cardiolipin
Schlame, M., Rua, D., & Greenberg, M. L. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00005-9 · Cited by 810 · see citing works
Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 802 · see citing works
Late Mortality Experience in Five-Year Survivors of Childhood and Adolescent Cancer: The Childhood Cancer Survivor Study
Mertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 796 · see citing works
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
Legha, S. S., Benjamin, R. S., MACKAY, B., Ewer, M. S., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., & Freireich, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 762 · see citing works
Evaluation of Diffuse Myocardial Fibrosis in Heart Failure With Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping
Iles, L., Pflüger, H., Phrommintikul, A., Cherayath, J., Ciris, P. A., Gupta, S., Kaye, D. M., & Taylor, A. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.049 · Cited by 736 · see citing works
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Başar, E., Özdoğru, İ., Er, O. S., Çetinkaya, Y., Doğan, A., Oğuzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 708 · see citing works
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702 · see citing works
Liposomes for the sustained drug release in vivo
Blume, G., & Cevc, G. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90440-y · Cited by 701 · see citing works
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 680 · see citing works
Drug targeting
Torchilin, V. P. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00166-4 · Cited by 680 · see citing works
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 673 · see citing works
Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL
Xu, X.-O. H., Shah, P. K., Faure, E., Equils, O., Thomas, L. S., Fishbein, M. C., Luthringer, D., Xu, X., Rajavashisth, T. B., Yano, J., et al. (2001) · Circulation · doi:10.1161/hc5001.100631 · Cited by 668 · see citing works
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662 · see citing works
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S. P., York, M., Spicer, D. V., Jones, S. E., Wadler, S., Desai, A. V., Vogel, C. L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 661 · see citing works
Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium
Frantz, S., Kobzik, L., Kim, Y., Fukazawa, R., Medzhitov, R. M., Lee, R. T., & Kelly, R. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6709 · Cited by 645 · see citing works
Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.
Davies, K. J. A., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 633 · see citing works
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales‐Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632 · see citing works
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
Lipshultz, S. E., Rifai, N., Dalton, V., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 620 · see citing works
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
Safra, T., Muggia, F. M., Jeffers, S., Tsao-Wei, D. D., Groshen, S. G., Lyass, O., Henderson, R., Berry, G. J., & Gabizón, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618 · see citing works
Topoisomerase IIβ–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane
Lyu, Y. L., Kerrigan, J. E., Lin, C., Azarova, A. M., Tsai, Y., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 614 · see citing works
Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography
Jenkins, C., Bricknell, K., Hanekom, L., & Marwick, T. H. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.050 · Cited by 597 · see citing works
Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study
Armstrong, G. T., Kawashima, T. I., Leisenring, W. M., Stratton, K. L., Stovall, M., Hudson, M. M., Sklar, C. A., Robison, L. L., & Oeffinger, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1055 · Cited by 584 · see citing works
Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1
Piantadosi, C. A., Carraway, M. S., Babiker, A., & Suliman, H. B. (2008) · Circulation Research · doi:10.1161/01.res.0000338597.71702.ad · Cited by 580 · see citing works
Exercise as Cardiovascular Therapy
Shephard, R. J., & Balady, G. J. (1999) · Circulation · doi:10.1161/01.cir.99.7.963 · Cited by 572 · see citing works
Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Ky, B., Putt, M. E., Sawaya, H., French, B. C., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J. A., Carver, J. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 567 · see citing works
Extracellular Matrix Remodeling in Heart Failure
Weber, K. T. (1997) · Circulation · doi:10.1161/01.cir.96.11.4065 · Cited by 556 · see citing works
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A. T., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553 · see citing works
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D. M., Sandri, M. T., Martinoni, A., Tricca, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 547 · see citing works
Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.
Doroshow, J. H., & Davies, K. J. A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 542 · see citing works
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540 · see citing works
Delayed Enhancement and T2-Weighted Cardiovascular Magnetic Resonance Imaging Differentiate Acute From Chronic Myocardial Infarction
Abdel‐Aty, H., Zagrosek, A., Schulz‐Menger, J., Taylor, A. J., Messroghli, D., Kumar, A., Gross, M. C., Dietz, R., & Friedrich, M. G. (2004) · Circulation · doi:10.1161/01.cir.0000127428.10985.c6 · Cited by 538 · see citing works
Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles
Senior, J. H., Delgado, C., Fisher, D., Tilcock, C., & Gregoriadis, G. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90337-8 · Cited by 521 · see citing works
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517 · see citing works
Energy metabolism in heart failure
Ventura‐Clapier, R., Garnier, A., & Veksler, V. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055095 · Cited by 499 · see citing works
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A. G., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 490 · see citing works
Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease
Tebbi, C. K., London, W. B., Friedman, D. L., Villaluna, D., de Alarcón, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A. R., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 489 · see citing works
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemia
TAN, C. T. C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3 · Cited by 486 · see citing works
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473 · see citing works
Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer
Reulen, R. C. (2010) · JAMA · doi:10.1001/jama.2010.923 · Cited by 447 · see citing works
Transplasma-membrane redox systems in growth and development
Crane, F. L., SUN, I. L., Clark, M. G., Grebing, C., & Löw, H. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Bioenergetics · doi:10.1016/0304-4173(85)90013-8 · Cited by 446 · see citing works
Drug-polymer conjugates
Duncan, R. (1992) · Anti-Cancer Drugs · doi:10.1097/00001813-199206000-00001 · Cited by 445 · see citing works
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U. H., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 444 · see citing works
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T. A., Kerkhoven, R. M., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 417 · see citing works
Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology
Thomas Eschenhagen, A., Force, T. L., Ewer, M. S., Keulenaer, G. W. D., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J., Brutsaert, D. L., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 410 · see citing works
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 400 · see citing works
The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries
Assomull, R., Lyne, J. C., Keenan, N., Gulati, A., Bunce, N. H., Davies, S., Pennell, D. J., & Prasad, S. K. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm113 · Cited by 386 · see citing works
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 377 · see citing works
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vasquez-Vivar, J. M., Pavel Martasek, E., Hogg, N., Masters, B. S. S., Pritchard, K. A., & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366 · see citing works
A Clinician’s Guide to Tissue Doppler Imaging
Ho, C. Y., & Solomon, S. D. (2006) · Circulation · doi:10.1161/circulationaha.105.579268 · Cited by 361 · see citing works
Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer
Speyer, J. L., Green, M. D., Kramer, E. D., Rey, M. J., Sanger, J. J., Ward, C., Dubin, N., Ferrans, V. J., Stecy, P. J., Zeleniuch‐Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356 · see citing works
CARDIAC TOXICITY OF DAUNORUBICIN
Bonadonna, G., Monfardini, S., Marmont, A., Damasio, E. E., & Rossi, F. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92093-5 · Cited by 348 · see citing works
Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice
Tyynismaa, H., Mjosund, K. P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink, J. N., Paetau, A., & Suomalainen, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505551102 · Cited by 342 · see citing works
Short-term effect of dynamic exercise on arterial blood pressure.
Pescatello, L. S., Fargo, A. E., Leach, C. N., & Scherzer, H. H. (1991) · Circulation · doi:10.1161/01.cir.83.5.1557 · Cited by 337 · see citing works
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334 · see citing works
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology
Lopez-Sendon, J. L., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 329 · see citing works
Apoptosis of Endothelial Cells Precedes Myocyte Cell Apoptosis in Ischemia/Reperfusion Injury
Scarabelli, T. M., Stephanou, A., Rayment, N. B., Pasini, E., Comini, L., Curello, S., Ferrari, R., Knight, R. A., & Latchman, D. S. (2001) · Circulation · doi:10.1161/01.cir.104.3.253 · Cited by 328 · see citing works
Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study
Kaya, M. G., Özkan, M., Günebakmaz, Ö., Akkaya, H., Kaya, E., Akpek, M., Kalay, N., Dikilitaş, M., Yarlıoğlueş, M., Karaca, H., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.023 · Cited by 325 · see citing works
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch‐Jacquotte, A., Wernz, J., Rey, M. J., Sanger, J. J., Kramer, E. D., Ferrans, V. J., Höchster, H. S., & Meyers, M. I. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 321 · see citing works
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
van der Pal, H. J. H., van Dalen, E. C., van Delden, E., van Dijk, I. W. E. M., Kok, W. E. M., Geskus, R. B., Sieswerda, E., Oldenburger, F. R., Koning, C. C. E., van Leeuwen, F. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4730 · Cited by 318 · see citing works
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D. M., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313 · see citing works
Pharmacology of carvedilol
Dulin, B. R., & Abraham, W. T. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.003 · Cited by 312 · see citing works
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Rafiyath, S. M., Rasul, M. F., Lee, B., Wei, G., Lamba, G. S., & Liu, D. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-10 · Cited by 304 · see citing works
Coenzyme Q10 Prevents Apoptosis by Inhibiting Mitochondrial Depolarization Independently of Its Free Radical Scavenging Property
Papucci, L., Schiavone, N., Witort, E. J., Donnini, M., Lapucci, A., Tempestini, A., Formigli, L., Zecchi‐Orlandini, S., Orlandini, G., Carella, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302297200 · Cited by 303 · see citing works
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.
Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., & Papahadjopoulos, D. (1992) · PubMed · Cited by 297 · see citing works
Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function
Angelis, A. D., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., Ferreira-Martins, J., Zheng, H.-Q., Hosoda, T., Rota, M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.895771 · Cited by 295 · see citing works
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro
Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., & Patrone, F. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.024 · Cited by 293 · see citing works
Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292 · see citing works
Increased Human Brain Natriuretic Peptide in Congestive Heart Failure
Mukoyama, M., Nakao, K., Saito, Y., Ogawa, Y., Hosoda, K., Suga, S., Shirakami, G., Jougasaki, M., & Imura, H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009133231114 · Cited by 288 · see citing works
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Azarova, A. M., Lyu, Y. L., Lin, C., Tsai, Y., Lau, J. Y., Wang, J. C., & Liu, L. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704002104 · Cited by 287 · see citing works
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography
Hoffmann, R., von Bardeleben, S., ten Cate, F. J., Borges, A. C., Kasprzak, J. D., Firschke, C., Lafitte, S., Al‐Saadi, N., Kuntz‐Hehner, S., Engelhardt, M. F., et al. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi083 · Cited by 284 · see citing works
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
Minow, R. A., Benjamin, R. S., & Gottlieb, J. A. (1975) · Cited by 274 · see citing works
Comparison and reproducibility of visual echocardiographic and quantitative radionyclide left ventricular ejection fractions
van Royen, N., Jaffe, C. C., Krumholz, H. M., Johnson, K. M., Lynch, P. J., Natale, D., Atkinson, P., Demon, P., & Wackers, F. J. T. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89179-5 · Cited by 268 · see citing works
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 268 · see citing works
Antioxidants and Cancer Therapy: A Systematic Review
Ladas, E. J., Jacobson, J. S., Kennedy, D. D., Teel, K., Fleischauer, A. T., & Kelly, K. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.086 · Cited by 260 · see citing works
Decreasing Late Mortality Among Five-Year Survivors of Cancer in Childhood and Adolescence: A Population-Based Study in the Nordic Countries
Möller, T. R., Garwicz, S., Barlow, L., Winther, J. F., Glattre, E., Ólafsdóttir, G. H., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3173 · Cited by 258 · see citing works
Adriamycin cardiomyopathy—risk factors
Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4 · Cited by 252 · see citing works
Differential effects of exercise on serum lipid and lipoprotein levels seen with changes in body weight. A meta-analysis
Tran, Z. V. (1985) · JAMA · doi:10.1001/jama.254.7.919 · Cited by 250 · see citing works
Adriamycin cardiotoxicity: a survey of 1273 patients.
Praga, C., Beretta, G., Pl, V., Gr, L., Pollini, C., Bonadonna, G., Canetta, R. M., Castellani, R., Villa, E., Cg, G., et al. (1979) · PubMed · Cited by 248 · see citing works
Emerging and diverse roles of protein kinase C in immune cell signalling
Tan, S., & Parker, P. J. (2003) · Biochemical Journal · doi:10.1042/bj20031406 · Cited by 247 · see citing works
N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?
Sandri, M. T., Salvatici, M., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., León, M. I., Civelli, M., Martinelli, G., & Cipolla, C. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050153 · Cited by 246 · see citing works
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Zhao, Y., McLaughlin, D., Robinson, E., Harvey, A., Hookham, M. B., Shah, A. M., McDermott, B. J., & Grieve, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2664 · Cited by 244 · see citing works
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
Ewer, M. S., Ali, M. K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S., Benjamin, R. S., & Haynie, T. P. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.2.112 · Cited by 244 · see citing works
A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form
Waterhouse, D., Tardi, P. G., Mayer, L. D., & Bally, M. B. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00004 · Cited by 242 · see citing works
Prognostic Significance of Strain Doppler Imaging in Light-Chain Amyloidosis
Koyama, J., & Falk, R. H. (2010) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.11.013 · Cited by 242 · see citing works
Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt
Fukazawa, R. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.09.012 · Cited by 239 · see citing works
Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet.
Gabizón, A. (2001) · PubMed · Cited by 236 · see citing works
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235 · see citing works
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group
Salzer, W. L., Devidas, M., Carroll, W. L., Winick, N. J., Pullen, J., Hunger, S. P., & Camitta, B. M. (2009) · Leukemia · doi:10.1038/leu.2009.261 · Cited by 233 · see citing works
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab
Hare, J., Brown, J. K., Leano, R., Jenkins, C., Woodward, N. E., & Marwick, T. H. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.031 · Cited by 228 · see citing works
Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227 · see citing works
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley, A. L., Liu, L. F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F. C., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 225 · see citing works
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics
Sarosiek, K. A., Fraser, C. S., Muthalagu, N., Bhola, P. D., Chang, W., McBrayer, S. K., Cantlon, A., Fisch, S., Golomb‐Mello, G., Ryan, J. A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.11.011 · Cited by 224 · see citing works
Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice
Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004) · Circulation · doi:10.1161/01.cir.0000146889.46519.27 · Cited by 224 · see citing works
Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
Ferrans, V. J. (1978) · PubMed · Cited by 220 · see citing works
Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging
Hundley, W. G., Kizilbash, A. M., Afridi, I., Franco, F., Peshock, R. M., & Grayburn, P. A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00409-4 · Cited by 220 · see citing works
Doxorubicin-induced persistent oxidative stress to cardiac myocytes
Zhou, S., Palmeira, C. M., & Wallace, K. B. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00329-0 · Cited by 219 · see citing works
Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy
Lebrecht, D., Setzer, B., Ketelsen, U., Haberstroh, J., & Walker, U. A. (2003) · Circulation · doi:10.1161/01.cir.0000093196.59829.df · Cited by 216 · see citing works
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study
Tassan‐Mangina, S., CODOREAN, D., Métivier, M., COSTA, B., Himberlin, C., Jouannaud, C., BLAISE, A., Elaerts, J., & Nazeyrollas, P. (2005) · European Journal of Echocardiography · doi:10.1016/j.euje.2005.04.009 · Cited by 212 · see citing works
Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway
Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, Y., Takanabe‐Mori, R., Nishi, E., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq148 · Cited by 208 · see citing works
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M. M., Brasseur, R., & Ruysschaert, J. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 201 · see citing works
Adriamycin-induced Cardiomyocyte and Endothelial Cell Apoptosis: In Vitro and In Vivo Studies
Wu, S. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2110 · Cited by 199 · see citing works
Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography.
Cranney, G. B., Lotan, C., Dean, L. S., Baxley, W. A., Bouchard, A., & Pohost, G. M. (1990) · Circulation · doi:10.1161/01.cir.82.1.154 · Cited by 198 · see citing works
Analyses of the Molecular Mechanism of Adriamycin-Induced Cardiotoxicity
Gille, L., & Nohl, H. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00025-7 · Cited by 198 · see citing works
Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison With Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging
Walker, J. R., Bhullar, N., Fallah‐Rad, N., Lytwyn, M., Golian, M., Fang, T., Summers, A. R., Singal, P. K., Barač, I., Kirkpatrick, I. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7294 · Cited by 197 · see citing works
Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome
Methe, H., Kim, J., Kofler, S., Weis, M., Näbauer, M., & Koglin, J. (2005) · Circulation · doi:10.1161/circulationaha.104.498865 · Cited by 193 · see citing works
Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS
Wang, W., Ha, C. H., Jhun, B. S., Wong, C. N., Jain, M. K., & Jin, Z. (2009) · Blood · doi:10.1182/blood-2009-05-224824 · Cited by 191 · see citing works
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Geisberg, C. A., & Sawyer, D. B. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0146-y · Cited by 189 · see citing works
Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer
Jurcut, R. O., Wildiers, H. P. M. W., Gáname, J., D’hooge, J., Backer, J. F. A. D., Denys, H. G., Paridaens, R., Rademakers, F. E., & Voigt, J. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.10.005 · Cited by 185 · see citing works
Elevated B-type natriuretic peptide levels after anthracycline administration
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., Kurabayashi, M., Yamaoki, K., Mitani, K., Hirai, H., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89908 · Cited by 184 · see citing works
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase
SPALLAROSSA, P., ALTIERI, P., GARIBALDI, S., GHIGLIOTTI, G., BARISIONE, C., MANCA, V, FABBI, P., BALLESTRERO, A., BRUNELLI, C., & BARSOTTI, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.009 · Cited by 182 · see citing works
Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011) · Pediatric Cardiology · doi:10.1007/s00246-010-9878-3 · Cited by 179 · see citing works
Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab
Putt, M. E., Hahn, V. S., Januzzi, J. L., Sawaya, H., Sebag, I. A., Plana, J. C., Picard, M. H., Carver, J. R., Halpern, E. F., Kuter, I., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241232 · Cited by 178 · see citing works
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Lipshultz, S. E., Miller, T. L., Lipsitz, S. R., Neuberg, D. S., Dahlberg, S. E., Colan, S. D., Silverman, L. B., Henkel, J. M., Franco, V. I., Cushman, L. L., et al. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0727 · Cited by 175 · see citing works
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. L. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174 · see citing works
The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardium
Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.541 · Cited by 172 · see citing works
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults
Dodos, F., Halbsguth, T. V., Erdmann, E., & Hoppe, U. C. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0633-6 · Cited by 172 · see citing works
The cardiotoxicity of adriamycin and daunomycin in children
Gilladoga, A. C., Manuel, C., TAN, C. T. C., Wollner, N., Sternberg, S. S., & Murphy, M. L. (1976) · Cancer · doi:10.1002/1097-0142(197602)37:2+ · Cited by 171 · see citing works
Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in Mice
Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiß, H., Kroemer, H. K., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.004 · Cited by 170 · see citing works
Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin
Miranda, C. J., Makui, H., Soares, R., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., & Santos, M. M. (2003) · Blood · doi:10.1182/blood-2003-03-0869 · Cited by 168 · see citing works
Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin
Neilan, T. G., Blake, S. L., Ichinose, F., Raher, M. J., Buys, E. S., Jassal, D. S., Furutani, E., Pérez-Sanz, T. M., Graveline, A. R., Janssens, S. P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.652339 · Cited by 167 · see citing works
Cardiac Magnetic Resonance Monitors Reversible and Irreversible Myocardial Injury in Myocarditis
Zagrosek, A., Abdel‐Aty, H., Boyé, P., Waßmuth, R., Messroghli, D., Utz, W., Rudolph, A., Bohl, S., Dietz, R., & Schulz‐Menger, J. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.09.014 · Cited by 167 · see citing works
Doxorubicin induces senescence and impairs function of human cardiac progenitor cells
Piegari, E., Angelis, A. D., Cappetta, D., Russo, R., Esposito, G., Costantino, S., Graiani, G., Frati, C., Prezioso, L., Berrino, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0334-4 · Cited by 166 · see citing works
Cardiotoxicity in Childhood Cancer Survivors: Strategies for Prevention and Management
Harake, D. E., Franco, V. I., Henkel, J. M., Miller, T. L., & Lipshultz, S. E. (2012) · Future Cardiology · doi:10.2217/fca.12.44 · Cited by 166 · see citing works
Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1
Denard, B. S., Lee, C., & Ye, J. (2012) · eLife · doi:10.7554/elife.00090 · Cited by 164 · see citing works
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini, M., Michelotti, A., Mastro, L. D., Gallo, L., Carnino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R. C., Pronzato, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3112 · Cited by 163 · see citing works
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study
Waßmuth, R., Lentzsch, S., Erdbrüegger, U., Schulz‐Menger, J., Doerken, B., Dietz, R., & Friedrich, M. G. (2001) · American Heart Journal · doi:10.1067/mhj.2001.115436 · Cited by 160 · see citing works
Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration
Serrano, J. A., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00011-0 · Cited by 159 · see citing works
Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage
Tatlıdede, E., Şehırlı, Ö., Velioğlu‐Öğünç, A., Çetınel, Ş., Yeğen, B. Ç., Yarat, A., Süleymanoğlu, S., & Şener, G. (2009) · Free Radical Research · doi:10.1080/10715760802673008 · Cited by 156 · see citing works
Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function
Gustafsson, F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00845-x · Cited by 156 · see citing works
Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer
Chow, E. J., Chen, Y., Hudson, M. M., Feijen, E. A. M., Kremer, L. C. M., Border, W. L., Green, D. M., Meacham, L. R., Mulrooney, D. A., Ness, K. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8673 · Cited by 154 · see citing works
Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages
Daemen, T., Hofstede, G., ten Kate, M. T., Bakker‐Woudenberg, I. A. J. M., & Scherphof, G. L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610520 · Cited by 153 · see citing works
Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload
HA, T., LI, Y., HUA, F., MA, J., Gao, X. J., Kelley, J., Zhao, A. T., Haddad, G. E., WILLIAMS, D., & WILLIAMBROWDER, I. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.05.025 · Cited by 152 · see citing works
A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary report
Ansfield, F. J., Klotz, J. H., Nealon, T. F., Ramírez, G., MINTON, J. P., Hill, G. J., Wilson, W., Davis, H. L., & Cornell, G. N. (1977) · Cancer · doi:10.1002/1097-0142(197701)39:1 · Cited by 152 · see citing works
Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., YU, Z., Takeda, K., & Ferrans, V. J. (1998) · PubMed · Cited by 151 · see citing works
Tissue‐specific mtDNA lesions and radical‐associated mitochondrial dysfunction in human hearts exposed to doxorubicin
Lebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A. (2005) · The Journal of Pathology · doi:10.1002/path.1863 · Cited by 149 · see citing works
Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity
Chicco, A. J., Hydock, D. S., Schneider, C. M., & Hayward, R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00148.2005 · Cited by 144 · see citing works
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
McKillop, J. H., Bristow, M. R., Goris, M. L., Billingham, M. E., & Bockemuehl, K. (1983) · American Heart Journal · doi:10.1016/0002-8703(83)90651-8 · Cited by 144 · see citing works
Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle
Rivello, H. G., Taranda, J., Said, M., Meckert, P. M. C., Petroff, M. V., Scaglione, J., Ghio, S., Chen, J., Lai, C., Laguens, R. P., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00048.2005 · Cited by 143 · see citing works
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani, I., Jain, D., Joska, T. M., Burtness, B. A., & Zaret, B. L. (2003) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2003.7 · Cited by 140 · see citing works
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., Skubitz, K. M., Rivera, E., Sparano, J. A., DiBella, N. J., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.010 · Cited by 139 · see citing works
NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis
Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Nevière, R., & Lancel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.085 · Cited by 139 · see citing works
Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity
Seifert, C. F., Nesser, M. E., & Thompson, D. F. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800912 · Cited by 139 · see citing works
Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats
Lebrecht, D., Geist, A., Ketelsen, U., Haberstroh, J., Setzer, B., & Walker, U. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707294 · Cited by 136 · see citing works
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms
Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)78025-8 · Cited by 135 · see citing works
Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice
Dolinsky, V. W., Rogan, K. J., Sung, M. M., Zordoky, B. N., Haykowsky, M. J., Young, M. E., Jones, L. W., & Dyck, J. R. B. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00044.2013 · Cited by 133 · see citing works
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies
Yoon, G., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.023 · Cited by 132 · see citing works
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M., Bjork, J. A., & Wallace, K. B. (2010) · Toxicology · doi:10.1016/j.tox.2010.01.019 · Cited by 131 · see citing works
Plasma levels of natriuretic peptides in relation to doxorubicin‐induced cardiotoxicity and cardiac function in children with cancer
Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., & Sakurai, M. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1155 · Cited by 130 · see citing works
Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential
Cheng, J., Kamiya, K., & Kodama, I. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00061.x · Cited by 129 · see citing works
A study on the toxic effects of doxorubicin on the histology of certain organs
Reddy, A., Anjaneyulu, Y., Shivakumar, P., & Rani, M. (2012) · Toxicology International · doi:10.4103/0971-6580.103656 · Cited by 127 · see citing works
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126 · see citing works
Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II Study
Treat, J., Greenspan, A., Forst, D. A., Sanchez, J., Ferrans, V. J., Potkul, L., Woolley, P. V., & Rahman, A. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.21.1706 · Cited by 123 · see citing works
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff, B. B., & Herman, E. H. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0023-3 · Cited by 123 · see citing works
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini, A., Berruti, A., Bersiga, A., Brizzi, M. P., Brunelli, A., Gorzegno, G., DiMarco, B., Aguggini, S., Bolsi, G., Cirillo, F., et al. (2000) · PubMed · Cited by 123 · see citing works
Cancer and Cardiac Mortality Among 15-Year Survivors of Cancer Diagnosed During Childhood or Adolescence
Green, D. M., Hyland, A. J., Chung, C. S., Zevon, M. A., & Hall, B. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3207 · Cited by 121 · see citing works
Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman, E., Ferrans, V. J., Myers, C. E., & Vleet, J. F. V. (1985) · PubMed · Cited by 120 · see citing works
Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study
Faber, J., Wingerter, A., Neu, M. A., Henninger, N., Eckerle, S., Münzel, T. F., Lackner, K. J., Beutel, M. E., Blettner, M., Rathmann, W., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy026 · Cited by 119 · see citing works
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118 · see citing works
Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure
Liu, F.-F., Stone, J. R., Schuldt, A. J. T., Okoshi, K., Okoshi, M. P., Nakayama, M., Ho, K. K. L., Manning, W. J., Marchionni, M. A., Lorell, B. H., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00268.2005 · Cited by 116 · see citing works
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
Vrooman, L. M., Neuberg, D. S., Stevenson, K. E., Asselin, B. L., Athale, U. H., Clavell, L. A., Cole, P. D., Kelly, K. M., Larsen, E. C., Laverdière, C., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.022 · Cited by 116 · see citing works
Role of mtDNA lesions in anthracycline cardiotoxicity
Lebrecht, D., & Walker, U. A. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0009-1 · Cited by 115 · see citing works
Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.
Toko, H., Oka, T., Zou, Y.-Z., Sakamoto, M., Mizukami, M., Sano, M., Yamamoto, R., Sugaya, T., & Komuro, I. (2002) · Hypertension Research · doi:10.1291/hypres.25.597 · Cited by 115 · see citing works
Formaldehyde crosslinks daunorubicin and DNA efficiently: HPLC and x-ray diffraction studies
Wang, A. H. ‐., Gao, Y., Liaw, Y. C., & Li, Y. K. (1991) · Biochemistry · doi:10.1021/bi00230a002 · Cited by 115 · see citing works
Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma
Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., & Iacono, A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90030-2 · Cited by 114 · see citing works
Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity
de Geus‐Oei, L., Mavinkurve‐Groothuis, A. M. C., Bellersen, L., Gotthardt, M., Oyen, W. J. G., Kapusta, L., & van Laarhoven, H. W. M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.082784 · Cited by 114 · see citing works
Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat
Sacco, G., Bigioni, M., Evangelista, S., Goso, C., Manzini, S., & Maggi, C. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00782-8 · Cited by 113 · see citing works

Flagged first, then by citations

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
Doxorubicin-induced cardiotoxicity and risk factors
Belger, C., Abrahams, C., Imamdin, A., & Lecour, S. (2023) · International Journal of Cardiology: Heart & Vasculature · doi:10.1016/j.ijcha.2023.101332 · Cited by 113 · see citing works
Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy
Han, N., Yang, Z., Xie, Z.-X., Xu, H., Yu, T., Li, Q., Li, L.-G., Peng, X., Yang, X., Hu, J., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154682 · Cited by 90 · see citing works
Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy
Huang, C., Guo, Y., Li, T., Sun, G., Yang, J., Wang, Y., Xiang, Y., Wang, L., Jin, M., Li, J., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2023.103024 · Cited by 76 · see citing works
Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats
Hekmat, A. S., Chenari, A., Alipanah, H., & Javanmardi, K. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00494-x · Cited by 72 · see citing works
Ferroptosis and its role in cardiomyopathy
Li, D., Pi, W., Sun, Z., Liu, X., & Jiang, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113279 · Cited by 72 · see citing works
Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies?
Al-Mahayri, Z. N., AlAhmad, M. M., & Ali, B. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710163 · Cited by 56 · see citing works
Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts
Mancilla, T. R., Davis, L. R., & Aune, G. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238856 · Cited by 54 · see citing works
Self-citation
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics
Adhikari, A., Asdaq, S. M. B., Hawaj, M. A. A., Chakraborty, M., Thapa, G., Bhuyan, N. R., Imran, M., Alshammari, M. K., Alshehri, M. M., Harshan, A. A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14100970 · Cited by 55 · see citing works
Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy
Su, X., Zhang, X., Liu, W., Yang, X., An, N., Yang, F., Sun, J., Xing, Y., & Shang, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.003 · Cited by 47 · see citing works
The Battlefield of Chemotherapy in Pediatric Cancers
Bo, L., Wang, Y., Li, Y., Wurpel, J. N. D., Huang, Z., & Chen, Z. (2023) · Cancers · doi:10.3390/cancers15071963 · Cited by 44 · see citing works
Nanomedicine and graphene-based materials: advanced technologies for potential treatments of diseases in the developing nervous system
Cellot, G., Biagioni, A. F., & Ballerini, L. (2021) · Pediatric Research · doi:10.1038/s41390-021-01681-6 · Cited by 44 · see citing works
Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice
Reis-Mendes, A., Padrão, A. I., Duarte, J. A., Gonçalves‐Monteiro, S., Duarte‐Araújo, M., Remião, F., Carvalho, F. D., Sousa, E., Bastos, M. D. L., & Costa, V. M. (2021) · Biomolecules · doi:10.3390/biom11111725 · Cited by 43 · see citing works
Overview on the Side Effects of Doxorubicin
Ajaykumar, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94896 · Cited by 37 · see citing works
Endoplasmic Reticulum Stress Promotes iNOS/NO and Influences Inflammation in the Development of Doxorubicin-Induced Cardiomyopathy
Bagchi, A. K., Malik, A., Akolkar, G., Jassal, D. S., & Singal, P. K. (2021) · Antioxidants · doi:10.3390/antiox10121897 · Cited by 32 · see citing works
Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
Bhagat, A., Shrestha, P., Jeyabal, P., Peng, Z., Watowich, S. S., & Kleinerman, E. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947604 · Cited by 32 · see citing works
Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
Sobiborowicz, A., Kamińska, K., & Cudnoch‐Jędrzejewska, A. (2023) · Cancers · doi:10.3390/cancers15010312 · Cited by 33 · see citing works
Pediatric Rhabdomyosarcomas of the Genitourinary Tract
Castle, J. T., Levy, B. E., Allison, D. B., Rodeberg, D. A., & Rellinger, E. J. (2023) · Cancers · doi:10.3390/cancers15102864 · Cited by 29 · see citing works
Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders
Pastorczak, A. K., Attarbaschi, A., Bomken, S. N., Borkhardt, A., ten Bosch, J. V. D. W., Elitzur, S., Gennery, A. R., Hlaváčková, E. O., Kerekes, A., Křenová, Z., et al. (2022) · Cancers · doi:10.3390/cancers14082000 · Cited by 27 · see citing works
Investigation of the impact of rosuvastatin and telmisartan in doxorubicin-induced acute cardiotoxicity
Al-Kuraishy, H. M., Al-Gareeb, A. I., ALKHURIJI, A. F., Al‐Megrin, W. A. I., Elekhnawy, E., Negm, W. A., WAARD, M. M. D., & Batiha, G. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113673 · Cited by 29 · see citing works
Ferruginol Restores SIRT1-PGC-1α-Mediated Mitochondrial Biogenesis and Fatty Acid Oxidation for the Treatment of DOX-Induced Cardiotoxicity
Li, W., Cao, J., Wang, X., Zhang, Y., Sun, Q., Jiang, Y., Yao, J., Li, C., Wang, Y., & Wang, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.773834 · Cited by 26 · see citing works
Emerging and Ongoing Survivorship Challenges Among Childhood Cancer Survivors and Providing Risk-Based Focused Follow-Up Care
Bashore, L. M., & Hobbie, W. L. (2021) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2021.151163 · Cited by 25 · see citing works
Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models
Jia, D., Yang, Y., Yuan, F., Fan, Q., Wang, F., Huang, Y., Song, H., Hu, P., Wang, R., Li, G., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119541 · Cited by 24 · see citing works
Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
Singh, M., Nicol, A. T., DelPozzo, J., Wei, J., Singh, M., Nguyen, T., Kobayashi, S., & Liang, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.839644 · Cited by 24 · see citing works
Didymin attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress
Chen, R., Sun, G., Xu, L., Zhang, X., Zeng, W., & Sun, X. (2021) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2021.07.002 · Cited by 21 · see citing works
Advances in Cardiotoxicity Induced by Altered Mitochondrial Dynamics and Mitophagy
Yin, Y., & Shen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.739095 · Cited by 21 · see citing works
Redox signaling in the pathogenesis of human disease and the regulatory role of autophagy
Pervaiz, S., Bellot, G. L., Lemoine, A., & Brenner, C. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.03.002 · Cited by 20 · see citing works
Anthracycline in Medicinal Chemistry: Mechanism of Cardiotoxicity, Preventive and Treatment Strategies
Hussen, N. H., Hasan, A. H., Muhammed, G. O., Yassin, A. Y., Salih, R. R., Esmail, P. A., Alanazi, M. M., & Jamalis, J. (2023) · Current Organic Chemistry · doi:10.2174/1385272827666230423144150 · Cited by 19 · see citing works
Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat
Kala, P., Bartušková, H., Pitha, J. V., Vaňourková, Z., Kikerlová, S., Jíchová, Š., Melenovský, V., Hošková, L., Veselka, J., Kompanowska‐Jezierska, E., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249337 · Cited by 19 · see citing works
The protection afforded by Berberine against chemotherapy‐mediated nephropathy in rats involves regulation of the antioxidant axis
Alagal, R. I., AlFaris, N. A., Alshammari, G. M., ALTAMIMI, J. Z., ALMOUSA, L. A., & Yahya, M. A. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13807 · Cited by 15 · see citing works
Prospective affirmative therapeutics of cannabidiol oil mitigates doxorubicin-induced abnormalities in kidney function, inflammation, and renal tissue changes
Soliman, N. A., Dahmy, S. I. E., Shalaby, A. A., & Mohammed, K. A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02836-4 · Cited by 15 · see citing works
Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity
Buchalska, B., Kamińska, K., Kowara, M., Sobiborowicz, A., & Cudnoch‐Jędrzejewska, A. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09952-4 · Cited by 13 · see citing works
Cardio-Oncology in Childhood: State of the Art
Bennati, E., Girolami, F., Spaziani, G., Calabri, G. B., Favre, C., Parrini, I., Lucà, F., Tamburini, A., & Favilli, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01329-6 · Cited by 12 · see citing works
Long noncoding RNA RMRP ameliorates doxorubicin-induced apoptosis by interacting with PFN1 in a P53-Dependent manner
Li, J., Zhou, L., Jiang, Y., Gao, H., Tuersuntuoheti, M., & Gong, H. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101937 · Cited by 12 · see citing works
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies
Illiano, M. L., Colinard, M., Taque, S., Mallon, B., Larue, C., Laithier, V., Verite-Goulard, C., Sudour‐Bonnange, H., Faure‐Conter, C., Coze, C., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10251-1 · Cited by 12 · see citing works
Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis
Luo, J., He, M., Liang, C., Huang, X., Zhu, Y., Hu, D., Yan, J., Li, M., Lin, H., Liao, W., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117183 · Cited by 11 · see citing works
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients
Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10 · see citing works
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies
Armstrong, A. E., Daw, N. C., Renfro, L. A., Geller, J. I., Kalapurakal, J. A., Khanna, G., Paulino, A. C., Perlman, E. J., Ehrlich, P. F., Gow, K. W., et al. (2025) · Cancer · doi:10.1002/cncr.35713 · Cited by 10 · see citing works
IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity
Ji, H.-Y., Ma, W.-Y., Liu, X., Chen, H.-Y., Liu, Y.-N., Ren, Z., Yin, D.-H., Cai, A., Zhang, Z.-Z., Wang, X., et al. (2025) · Experimental and Molecular Medicine · doi:10.1038/s12276-024-01389-7 · Cited by 12 · see citing works
Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors
Curren, V., Dham, N., & Spurney, C. F. (2021) · Hearts · doi:10.3390/hearts2010005 · Cited by 10 · see citing works
Anesthesia in Children with Neuroblastoma, Perioperative and Operative Management
Tognon, C., Pulvirenti, R., Fati, F., Corti, F. D., Viscardi, E., Volpe, A., & Gamba, P. (2021) · Children · doi:10.3390/children8050395 · Cited by 9 · see citing works
Modeling propofol‐induced cardiotoxicity in the isolated‐perfused newborn mouse heart
Barajas, M. B., Wang, A., Griffiths, K. K., Sun, L., Yang, G., & Levy, R. J. (2022) · Physiological Reports · doi:10.14814/phy2.15402 · Cited by 9 · see citing works
Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in doxorubicin-induced kidney injury in rats
Elgohary, A., Metwalli, F., Mostafa, N. Y., Refaat, M., & El-Khawaga, O. Y. (2023) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-023-00194-5 · Cited by 9 · see citing works
Effects of Cardiotoxins on Cardiac Stem and Progenitor Cell Populations
Smith, A. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.624028 · Cited by 9 · see citing works
Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity—A Literature Review
Tamehrizadeh, S. S., Khalaji, M., Tajdari, M., Mavaddat, H., Szmit, S., Lashgari, N., Roudsari, N. M., Abbasi-Kashkoli, H., Banach, M., & Abdolghaffari, A. H. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10030-6 · Cited by 8 · see citing works
Drug-Induced Cardiotoxicity in Children During the Past 30 Years: A Bibliometric Study and Visualization Analysis
Wu, M., Yang, Y., Cao, M., Liu, T., Tian, Y., Zhao, Z., & Zhu, B. (2023) · Medical Science Monitor · doi:10.12659/msm.938673 · Cited by 8 · see citing works
Can antioxidant vitamins avoid the cardiotoxicity of doxorubicin in treating breast cancer?
Cavalcanti, I. D. L., Medeiros, S. M. D. F. R. D. S., Medeiros, S. M. D. F. R. D. S., Cavalcanti, I. M. F., & Nogueira, M. C. D. B. L. (2021) · PharmaNutrition · doi:10.1016/j.phanu.2021.100259 · Cited by 8 · see citing works
Long Non-coding RNAs: Potential Players in Cardiotoxicity Induced by Chemotherapy Drugs
Amrovani, M., Mohammadtaghizadeh, M., Aghaali, M. K., Zamanifard, S., Alqasi, A., & Sanei, M. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09681-y · Cited by 8 · see citing works
Advances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis
Jia, S., Gong, B., Chen, H., Chen, Y., Zhuo, C., Wu, H., Qu, X., & Cai, H. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s586319 · Cited by 7 · see citing works
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs
Reinal, I., Ontoria‐Oviedo, I., Selva, M., Casini, M., Peiró-Molina, E., Santos, C. F., Climent, A. M., Balaguer, J., Cañete, A., Mora, J., et al. (2023) · Antioxidants · doi:10.3390/antiox12071378 · Cited by 7 · see citing works
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury
Zhen, J., Yu, H., Ji, H., Cai, L., Leng, J., & Keller, B. B. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117070 · Cited by 7 · see citing works
Intensive chemotherapy perturbs heart rate variability in children with cancer
Çakan, P., Yıldız, S., Akyay, A., & Öncül, Y. (2021) · Neurophysiologie Clinique · doi:10.1016/j.neucli.2021.11.001 · Cited by 7 · see citing works
Combined Utility of Speckle Tracking Echocardiography and Cardiac Biomarkers for Early Detection of Anthracycline-Induced Cardiotoxicity in Pediatric Oncology Patients
Stolojanu, C., Steflea, R. M., Micsescu-Olah, A.-M., Alexandra, I., Popoiu, A., & Doros, G. S. (2024) · Biomedicines · doi:10.3390/biomedicines12122849 · Cited by 6 · see citing works
Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism, biomarkers and management
Amaan, M., Goel, R., Paul, S., & Danish, I. (2024) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v12i6.673 · Cited by 6 · see citing works
Nano-emulsion based on Santolina chamaecyparissus essential oil potentiates the cytotoxic and apoptotic effects of Doxorubicin: an in vitro study
AlMotwaa, S. M., & Al‐Otaibi, W. A. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2386287 · Cited by 6 · see citing works
Abdominal Tumors
Castle, J. T., Levy, B. E., & Rodeberg, D. A. (2022) · Surgical Clinics of North America · doi:10.1016/j.suc.2022.07.006 · Cited by 6 · see citing works
Endoplasmic reticulum stress in cardiomyopathies: from the unfolded protein response to therapeutic opportunities
Qiu, Y., Chen, Z., He, P., & Wang, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1577186 · Cited by 5 · see citing works
The Impact of Metformin on the Development of Hypothyroidism and Cardiotoxicity Induced by Cyclophosphamide, Methotrexate, and Fluorouracil in Rats
Alhowail, A. H., & Aldubayan, M. A. (2023) · Pharmaceuticals · doi:10.3390/ph16091312 · Cited by 5 · see citing works
Micafungin protects mouse heart against doxorubicin-induced oxidative injury via suppressing MALT1-dependent k48-linked ubiquitination of Nrf2
Lu, L., Li, M.-R., Huang, L.-L., Che, Y.-X., Qi, Y., Luo, X., & Peng, J. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111179 · Cited by 5 · see citing works
Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats
Gawryś, O., Jíchová, Š., Miklovič, M., Husková, Z., Kikerlová, S., Sadowski, J., Kollárová-Brázdová, P., Lenčová-Popelová, O., Hošková, L., Imig, J. D., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01865-7 · Cited by 6 · see citing works
Pyruvate plus uridine augments mitochondrial respiration and prevents cardiac hypertrophy in zebrafish and H9c2 cells
Mukherjee, S., Das, S., Das, S., Gupta, S., Hui, S. P., Sengupta, A., & Ghosh, A. (2025) · Journal of Cell Science · doi:10.1242/jcs.263653 · Cited by 4 · see citing works
Evaluation of the Effect of Virgin Rice Bran Oil (VRBO) on Doxorubicininduced Cardiotoxicity in Wistar Rats
Prema, S., Verma, R., Nagarwal, A., Bharkatiya, M., Baghel, M., Kishore, L., Wal, P., & Gasmi, A. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x327970250108045235 · Cited by 3 · see citing works
Leonurine alleviates doxorubicin-induced myocarditis in mice via MAPK/ERK pathway inhibition
Tang, D. (2025) · American Journal of Translational Research · doi:10.62347/kwrf2732 · Cited by 3 · see citing works
Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis
Lukovic, D., Hašimbegović, E., Winkler, J., Mester-Tonczar, J., Zlabinger, K., Han, E., Spannbauer, A., Traxler, D., Bergler-Klein, J. K., Pávó, N., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087461 · Cited by 3 · see citing works
PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin
Julson, J. R., Quinn, C. H., Nazam, N., Bownes, L. V., Stewart, J. E., & Beierle, E. A. (2024) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2024.03.014 · Cited by 3 · see citing works
Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity
Meng, Y., Sun, J., Zhang, G., Yu, T., & Piao, H. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09925-7 · Cited by 3 · see citing works
Isosorbide dinitrate improves doxorubicin-induced cardiotoxicity via diminishing proinflammatory mediators, oxidative stress, and apoptosis
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.05.030 · Cited by 2 · see citing works
Ceramides: a potential cardiovascular biomarker in young adult childhood cancer survivors?
Broberg, O., Weismann, C. G., Øra, I., Wiebe, T., Laaksonen, R., & Liuba, P. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae026 · Cited by 2 · see citing works
Doxorubicin-induced Cardiomyopathy: Mechanisms, Diagnosis and Therapeutic Drugs
Huang, C., & Zhu, S. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v6i.954 · Cited by 2 · see citing works
A cohort study on blood coagulation in childhood cancer survivors
Meyer, A. D. J., Hughes, T. B., Rishmawi, A. R., Heard, P., Shah, S., & Aune, G. J. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.04.025 · Cited by 2 · see citing works
Self-citation
Effects of barakol from Cassia siamea on neuroblastoma SH-SY5Y cell line: A potential combined therapy with doxorubicin
Wongsawatkul, O., Buachan, P., Jaisin, Y., Busarakumtragul, P., Chainakul, S., Watanapokasin, R. Y., Prachayasittikul, V., Prachayasittikul, S., Ruchirawat, S., & Prachayasittikul, V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24694 · Cited by 2 · see citing works
Non‐alkylating agents‐induced gonadotoxicity in pre‐pubertal males: Insights on the clinical and pre‐clinical front
Sriram, S., Macedo, T., Mavinkurve‐Groothuis, A. M. C., van de Wetering, M. D., & Looijenga, L. H. J. (2024) · Clinical and Translational Science · doi:10.1111/cts.70075 · Cited by 2 · see citing works
Multiple analysis of mitochondrial metabolism, autophagy and cell death
Liu, D., Lai, H.-T., Peyre, F., & Brenner, C. (2021) · Methods in cell biology · doi:10.1016/bs.mcb.2021.02.001 · Cited by 2 · see citing works
Early use of angiotensin‐converting enzyme inhibitor and β‐blocker attenuated doxorubicin‐induced cardiomyopathy
Kume, K., Ueno, K., Kawamura, J., Okamoto, Y., & Kawano, Y. (2022) · Pediatrics International · doi:10.1111/ped.14880 · Cited by 2 · see citing works
Phoenix Dactylifera L. Tree Fruit Exerts Cardioprotective Effect Against DoxorubicinInduced Heart Damage in Rats via Inhibition of Oxidative Stress
Çoşkun, R., Çelik, A. İ., Coşgun, M. S., Dündar, C., Türkoğlu, M., & Süleyman, H. (2022) · Koşuyolu Heart Journal · doi:10.51645/khj.2022.m210 · Cited by 2 · see citing works
Importance of familial predisposition to heart failure to the risk of anthracycline-related cardiotoxicity: A nationwide study
Banke, A., Andersson, C., D’Souza, M., Fosbøl, E. L., Nielsen, D. L., Pedersen, C. T., Gislason, G., Møller, J. E., Køber, L., Rasmussen, C. M., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.07.001 · Cited by 1 · see citing works
Biocompatible supramolecular hydrogels based on polysaccharide-modified hyaluronic acid for targeted delivering of doxorubicin
Li, C., Zhou, Q., Huang, H., & Li, L. (2024) · Supramolecular chemistry · doi:10.1080/10610278.2024.2423637 · Cited by 1 · see citing works
Experimental evaluation of N-acetylcysteine against doxorubicin cardiotoxicity in rats
Tola, H. T., & Kılıç, S. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01073-0 · Cited by 1 · see citing works
EFFECT OF SELENIUM AND N-(P-AMYLCINNAMOYL) ANTHRANILIC ACID ON DOXORUBICIN-INDUCED KIDNEY INJURY IN RATS
Yıldızhan, K., Huyut, Z., Altındağ, F., & Uçar, B. (2022) · İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi · doi:10.33715/inonusaglik.1174849 · Cited by 1 · see citing works
Cardiac Mechanical Performance Assessment at Different Levels of Exercise in Childhood Acute Lymphoblastic Leukemia Survivors
Uwase, E., Caru, M., Curnier, D. Y., Abasq, M. M., Andelfinger, G., Krajinović, M., Laverdière, C., Sinnett, D., & Périé, D. (2023) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002682 · Cited by 1 · see citing works
Cytotoxic effect of Ziziphus Spina-Christi extract alone and in combination with doxorubicin on breast cancer cells
El‐Shafey, E. S., & Elsherbiny, E. S. (2023) · The Ukrainian Biochemical Journal · doi:10.15407/ubj95.06.050 · Cited by 1 · see citing works
CARDIOTOXICIDADE EM PACIENTES ONCOLÓGICOS PEDIÁTRICOS TRATADOS COM ANTRACICLINAS
Morais, M. C., Albuquerque, M. T. F., & Neto, J. G. D. O. (2023) · JNT - Facit Business and Technology Journal · doi:10.29327/2199304.1.43-33 · Cited by 1 · see citing works
Risk stratification and primary prevention of chemotherapy cardiotoxicity
Shilov, S. N., Березикова, Е. Н., Таировна, Б. Е., Tretyakov, S. V., Teplyakov, A. T., Grakova, E. V., Kopeva, K. V., & Filippov, A. A. (2024) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2024-39-4-187-193 · Cited by 1 · see citing works
Impact of corvitin and alpha-ketoglutarate on heart morphology, expression and activity of matrix metalloproteinases 2/9 in the heart of rats with doxorubicin-induced cardiomyopathy
Gordiienko, I. A., Poslavska, О. V., & Шевцова, А. И. (2019) · Regulatory Mechanisms in Biosystems · doi:10.15421/021956 · Cited by 1 · see citing works
Development and characterization of a mass cytometry panel for detecting the effect of acute doxorubicin exposure on murine cardiac nonmyocytes
Iskra, B. S., Davis, L., Miller, H. E., Chiu, Y., Bishop, A. J. R., Chen, Y., & Aune, G. J. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00514.2021 · Cited by 1 · see citing works
Self-citation
PET imaging of fibroblast activation protein alpha (FAP) detects incipient cardiotoxicity due to anthracycline chemotherapyPreprint
Lee, C., Manzo, O. L., Rubinelli, L., Carrasco, S. E., Cho, S., Jeitner, T. M., Babich, J. W., Lorenzo, A. D., & Kelly, J. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.03.556130 · Cited by 1 · see citing works
Doxorubicin-Induced Cardiotoxicity: Can Andrographolide Provide a Silver Lining?
Hulsurkar, M. M., & Wehrens, X. H. T. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07674-5 · Cited by 1 · see citing works
DYNAMICS OF NUMBER OF CARDIOMYOCYTES IN THE HEART UNDER ISOLATED AND COMBINED EXPOSURE OF DOXORUBICIN AND ATORVASTATIN
Геннадьевна, К. М., Владимировна, Т. Н., Клочкова, С. В., & Lushnikova, E. L. (2019) · Современные проблемы науки и образования · doi:10.17513/spno.29427
Das kraniofaziale Osteosarkom: eine interdisziplinäre Herausforderung
Bielack, S., Hecker‐Nolting, S., Kager, L., ten Langer, T. S., & Blattmann, C. (2021) · Der MKG-Chirurg · doi:10.1007/s12285-021-00316-3
Das kraniofaziale Osteosarkom: eine interdisziplinäre Herausforderung
Bielack, S., Hecker‐Nolting, S., Kager, L., ten Langer, T. S., & Blattmann, C. (2022) · best practice onkologie · doi:10.1007/s11654-022-00384-6
Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia
Pustelnik, E., Pikora, K., & Pawelec, K. M. (2023) · Nowotwory Journal of Oncology · doi:10.5603/njo.96144
Immunomodulatory potential of silver nanoparticles and therapeutic effect against doxorubicin-induced-cardiotoxicity in rats
Tarbiah, N. I., Khalifa, F. K., Alkhattabi, N. A., Ghazali, R. F., Alzahri, R. Y., Alkhodair, S. A., Shindi, R. A., & Mansour, A. A. (2024) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.22032
OS DESAFIOS DO ENFERMEIRO FRENTE À COMUNICAÇÃO COM PACIENTES ONCOLÓGICOS EM CUIDADOS PALIATIVOS: UMA REVISÃO INTEGRATIVA
Souza, R. M., Moreira, V. D. S., Souza, N. V. D. D. O., Peres, P. L. P., Marins, A. L. C., de Almeida, L. F., Rocha, R. S., Padilha, R. A., & de Andrade, K. B. S. (2024) · doi:10.22533/at.ed.4722410057
OCUPAÇÃO DE LEITOS DE TERAPIA INTENSIVA NA PANDEMIA DA COVID-19: PERSPECTIVAS GERENCIAIS DA ENFERMAGEM ONCOLÓGICA
Mazzoni, V. G., Marcellini, P. S., Carvalho, E. C., Muzi, C. D., de Mello, L. R. G., Marins, A. L. C., Carvalho, A. F. C., de Mesquita, A. M. F., Stipp, M. A. C., & de Andrade, K. B. S. (2024) · doi:10.22533/at.ed.47224100511
O MANEJO DA DOR PELA EQUIPE DE ENFERMAGEM NA ONCOLOGIA PEDIÁTRICA: UMA REVISÃO DE LITERATURA
da Silva, H. S., Varella, T. C. M. Y. M. L., Peres, P. L. P., Souza, N. V. D. D. O., Soares, S. S. S., de Farias, S. N. P., Monteiro, J. L. D. S., Pinheiro, A. P. B., de Almeida, C. G., Carvalho, E. C., et al. (2024) · doi:10.22533/at.ed.4722410051
EXENTERAÇÃO PÉLVICA EM PACIENTES COM CÂNCER GINECOLÓGICO
da Silva, D. A., Resende, R. I., Júnior, J. D. J. C., Muzi, C. D., Frias, T. F. P., Lima, V. C. G. S., Lopes, S. M., Pedrada, L. D. S. D. A., Padilha, R. A., & de Andrade, K. B. S. (2024) · doi:10.22533/at.ed.47224100510
HIPODERMÓCLISE EM PACIENTES ONCOLÓGICOS SOB CUIDADOS PALIATIVOS
Ramos, A. D. V., Sardou, M., Leite, D. C., Camerini, F. G., Peres, E. M., Assad, L. G., Sbano, C. P., Lima, V. C. G. S., de Menezes, R. F., Pires, A. D. S., et al. (2024) · doi:10.22533/at.ed.4722410055
A INFLUÊNCIA DA RELIGIOSIDADE E ESPIRITUALIDADE NO CUIDADO DE ENFERMAGEM AO PACIENTE ONCOLÓGICO TERMINAL
da Silva, S. T. F., Peres, P. L. P., de Andrade, K. B. S., de Andrade, P. C. D. S. T., COUTO, C. A. C., de Oliveira, A. M., & Varella, T. C. M. Y. M. L. (2024) · doi:10.22533/at.ed.4722410054
ANÁLISE DA PRODUÇÃO DE CONHECIMENTO SOBRE A NAVEGAÇÃO DE PACIENTES ONCOLÓGICOS EM PERIÓDICOS BRASILEIROS DE ENFERMAGEM
Maia, G. K. C., Ramos, R. D. S., Pimentel, N. B. L., Padilha, R. A., Peres, E. M., Pinheiro, A. P. B., Mazzoni, V. G., Rocha, R. G., da Costa, C. C. P., Marta, C. B., et al. (2024) · doi:10.22533/at.ed.4722410056
Saberes sobre o cuidado de enfermagem direcionado ao paciente oncológico: contribuições para a prática clínica
de Andrade, K. B. S., Carvalho, E. C., Souza, N. V. D. D. O., Varella, T. C. M. Y. M. L., & Soares, S. S. S. (2024) · doi:10.22533/at.ed.472241005

Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention
Bhagat, A., & Kleinerman, E. S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_15 · Cited by 208 · see citing works
Doxorubicin may damage cardiomyocytes more than cardiac progenitor cells
Edwards, J., Mitry, M. A., & Laurent, D. (2016) · The FASEB Journal · doi:10.1096/fasebj.30.1_supplement.735.7
G-13 Free Communication/Poster - Cardiovascular II
(2013) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000433761.34219.37
How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer
van den Anker, J. N. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0300-4 · Cited by 6 · see citing works
A genome-wide association study for doxorubicin-induced cardiomyopathy in childhood cancer survivors from the St. Jude lifetime cohort (SJLIFE) and the childhood cancer survivor (CCSS) studies.
Petrykey, K., Wang, H., Im, C., Dixon, S. B., Ehrhardt, M. J., Mulrooney, D. A., Sharafeldin, N., Wang, X., Jefferies, J. L., Oeffinger, K. C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.12088

Authors: Mancilla, T. R., Iskra, B., & Aune, G. J.
Affiliations: The University of Texas at San Antonio Health Science Center (US)
Corresponding author: Aune, Gregory J.
ORCID: Iskra, Brian
Aune, Gregory J.
Venue: Comprehensive Physiology
Publisher: Wiley
Published: 2019-06-12
Volume: 9
Issue: 3
Pages: 905-931
ISSN: 2040-4603 (ISSN-L)
DOI: 10.1002/cphy.c180017
PMC: PMC7000168
OpenAlex: W2953223155
Cited by: 108
References: 361
Citations by year: 2026: 3 · 2025: 11 · 2024: 28 · 2023: 21 · 2022: 16 · 2021: 21 · 2020: 5 · 2019: 3
Type: other
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
Locations: Comprehensive physiology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (F30AG057213)
National Institute of General Medical Sciences (T32GM113896)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: doxorubicin, cardiotoxicity, cardiomyopathy, childhood cancer survivors, cardiomyocytes, cardiac pathophysiology, childhood cancer, cardioprotection
MeSH terms: Age Factors, Antibiotics, Antineoplastic, Child, DNA Damage, Doxorubicin, Endothelium, Vascular, Humans, Mitochondria, Heart, Reactive Oxygen Species, Neuregulins, Myocytes, Cardiac, Cardiotoxicity, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxorubicin‐Induced Cardiomyopathy in Children

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks